75 pts with NSCLC were treated with carboplatin / gemzar, Protocol given consisted of carbo. at AUC 5 on D 1 and gem. 1000 mg/m 2 on D 1 and 8 Q3 weeks. There were 55 male and 20 female pts, their age ranged from 36 to 84 years (med 71 ), The PS was I in 53 ( 70 .6% ) and II in 22( 29.4%) pts. 27 (36%) pts had stage IIIb disease and 48 (64%) pts had st IV or recurrent disease. Treatment intent was neo -adjuvant in 8 (10.6%) pts and palliative in 67 (80.4% ) pts. Cycles received ranged from 1-15 ( med 5 ) percentage given ranged from 50 -100% ( med 80% ). Myelotoxicity gr III/IV was observed in 35(46.6%) pts and consisted mainly in anemia and thrombocytopenia, non hematologic toxicity gr III/IV was observed in 8 (10.6%) and consisted mainly in fatigue. Results: 14 ( 19.7% ) pts were not evaluable for response, PR was achieved in 21 (29.5%) pts., MR/SD in 16 (22.5%)pts, NR(no response) in 20 (28.1%) pts. Treatment was stopped in 43 (58.9%) pts due to maximal response, in 12 ((16.4%) pts due to toxicity and in 18 ( 24.6% )due to other reasons. Quality of life improved in 12( 7.3%), worsened in 42( 60.8%) and did not change in 15( 19%) pts. After completion of treatment 1 pt underwent surgery, 7 (9.5% ) pts had radiotherapy, 39 ( 53.4% ) pts received a second line treatment and 26 (35 .6) had supportive care. At a med. follow up of 10.9 months ( range 0.87 -41.6 )23 (30.65% ) pts. are alive with disease, 51 (68% ) pts are dead of disease. Kaplan -Mayer survival curves did not show differences among pts. in regards with gender or age (below and above 70 ).
The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC. Methods: Overall, 95 patients received pemetrexed 500 mg/m 2 i.v. over Day 1 of a 21-day cycle. Patients also received oral dexamethasone, oral folic acid and i.m. vitamin B12 supplementation to reduce toxicity. NCI CTC 2.0 was used to rate toxicity. All the adverse events were graded in terms of severity and relation to study treatment. Dose was reduced in case of toxicity and treatment was delayed for up to 42 days from Day 1 of any cycle to allow recovering from study drugrelated toxicities.Tumor response was measured using the RECIST criteria. Results: Patients received a median number of 4 cycles and 97.8% of the planned dose. Overall, 75 patients (78.9% of treated) reported at least one adverse event: 34 (35.8%) had grade 3 as worst grade and only 5 (5.2%) had grade 4. Drug-related events occurred in 57.9% of patients. Neutropenia (8.4%) and leukopenia (6.3 %) were the most common grade 3/4 hematological toxicities. Grade 3 anemia and thrombocytopenia were reported in 3.2% and 2.1% of patients,
